Anthos Therapeutics on LinkedIn: Atrial Fibrillation Study Shows Overwhelming Benefit for Abelacimab vsโฆ
#NEWS: Anthos Therapeutics today announced that the AZALEA TIMI-71 atrial fibrillation study with the dual-acting Factor XI / XIa inhibitor, abelacimab, wasโฆ